- Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.
- There was no correlation between the removal of amyloid plaques and cognitive function in the Biogen trial(s) in the highest dose group.
- In regards to Annovis, posiphen produced a 3.3 improvement in ADAS-cog scores over placebo at 25 days, but the improvement in the MMSE number was only .5.
- In an open-label trial at nine months, Cassava Sciences simufilam produced a 3 points improvement in ADAS-cog scores, which was up from 1.6 points at six months.
- Anavex 2-73 and panax ginseng lead to around a 3-point improvement in MMSE scores between 13 and 14 months, with a 10.4 point improvement in ADAS-cog scores for panax ginseng.
For further details see:
Detours In The Golden Age Of Alzheimer's Drug Stock Investments